💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Monomethyl Fumarate

CHEMBL589586 Phase 4 Aprobado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
130.1 g/mol
LogP
0.4
Phase
4

This metabolite of dimethyl fumarate activates the Nrf2 pathway to reduce oxidative stress and inflammation, and modulates immune cell populations involved in autoimmune attacks on the nervous system in multiple sclerosis. It represents the active compound responsible for the therapeutic effects of fumarate-based treatments for MS and psoriasis.

Peso molecular

130,1000 g/mol

LogP

0,40

TPSA

63,60 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Psoriasis Multiple Sclerosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COC(=O)/C=C/C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)/b3-2+

                

                

                

                    
                    

                        
Molecular Formula

                        
C5H6O4

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
Enlaces Rotables

                        
3

                    

                    
                    
                    

                        
Átomos Pesados

                        
9

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
This metabolite of dimethyl fumarate activates the Nrf2 pathway to reduce oxidative stress and inflammation, and modulates immune cell populations involved in autoimmune attacks on the nervous system in multiple sclerosis. It represents the active compound responsible for the therapeutic effects of fumarate-based treatments for MS and psoriasis.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Monomethyl Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL589586.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5369209.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.